CRC Research Update — September 11, 2026
Today's colorectal cancer research highlights
braf
A collection of 55 issues
Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case
Skip to content
The CRC Digest
Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case
A case report from the AGMT mCRC Registry describes successful rechallenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. (Clinical Colorectal Cancer)
This
ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC
Skip to content
The CRC Digest
▸ TREATMENT
ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC
A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge
Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC
Skip to content
The CRC Digest
◇ RESEARCH
Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC
Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.
CRC Research Update — September 04, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 03, 2026
Today's colorectal cancer research highlights
Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC
A population-based multicenter study examined real-world outcomes of the targeted therapy combination encorafenib plus panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. (Clinical Colorectal Cancer)
This content is informational only and
Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC
This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google
CRC Research Update — September 01, 2026
Today's colorectal cancer research highlights
Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era
Skip to content
The CRC Digest
Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era
A narrative review evaluates clinical integration of BRAF-targeted therapy combined with EGFR inhibition, addressing first-line treatment, MMR/MSI status, patient fitness, and sequencing strategies. (J Gastrointest Cancer)
This content is informational only and